These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
26. Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions. De Vita M; Coluccia V; Burzotta F; Romagnoli E; Trani C Curr Vasc Pharmacol; 2012 Jul; 10(4):448-53. PubMed ID: 22339256 [TBL] [Abstract][Full Text] [Related]
27. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553 [TBL] [Abstract][Full Text] [Related]
28. Acute profound thrombocytopenia following abciximab therapy. Bishara AI; Hagmeyer KO Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405 [TBL] [Abstract][Full Text] [Related]
29. Emergent operation for percutaneous coronary rupture after abciximab administration. Roberts CS; Bocanegra NR Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792 [TBL] [Abstract][Full Text] [Related]
30. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
31. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. Juran NB Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235 [TBL] [Abstract][Full Text] [Related]
33. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? Tcheng JE; Campbell ME J Am Coll Cardiol; 2003 Oct; 42(7):1196-8. PubMed ID: 14522479 [No Abstract] [Full Text] [Related]
34. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
35. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964 [TBL] [Abstract][Full Text] [Related]
36. [Role of glycoprotein IIb/IIIa inhibitors in the treatment of degenerated aortocoronary saphenous vein grafts]. Brück M; Ludwig J; Flachskampf FA; Daniel WG Z Kardiol; 2002 Jan; 91(1):16-23. PubMed ID: 11963202 [TBL] [Abstract][Full Text] [Related]
37. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A; Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766 [TBL] [Abstract][Full Text] [Related]
38. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395 [TBL] [Abstract][Full Text] [Related]
39. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). Chan AW; Moliterno DJ; Berger PB; Stone GW; DiBattiste PM; Yakubov SL; Sapp SK; Wolski K; Bhatt DL; Topol EJ; J Am Coll Cardiol; 2003 Oct; 42(7):1188-95. PubMed ID: 14522478 [TBL] [Abstract][Full Text] [Related]
40. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]